by Sean Hughes | Feb 1, 2021 | US & International
Key Revisions to the Chinese Guidelines for Patent Examination Supplementary Data Historically, in China, the rules on submitting supplementary data in favour of sufficiency and/or inventive step have been very strict throughout patent prosecution. This was bad news...
by Carolyn Haywood | Feb 1, 2021 | US & International
Background The patent at issue in the present case was US7,772,209, claim 1 of which is shown below. Claim 1 A method for administering pemetrexed disodium to a patient in need thereof comprising administering an effective amount of folic acid and an effective amount...
by Alex Bajjon | Jan 1, 2021 | Designs & Copyright, Trademarks, UK
A summary of the changes for 2021 and key points for right holders to note are provided below. Patents and Supplementary Protection Certificates (SPCs) The UK’s membership of the European Patent Convention and the ability for UK attorneys to represent clients...
by Alex Bajjon | Jan 1, 2021 | EPO
Previous Case Law It has previously been well-established that the EPO Boards of Appeal should not generally overturn findings of fact made by first instance examination or opposition decisions. EPO Decision T 1418/17 set out a limited number of circumstances in which...
by Eddie Bishop | Dec 1, 2020 | US & International
As a brief recap, claim 1 of Eli Lilly’s patent requires vitamin B12 + Pemetrexed disodium and claim 2 requires vitamin B12 + Pemetrexed disodium + folic binding protein. The potential infringer, Fresenius, used a composition including Pemetrexed tromethamine in...
Recent Comments